scholarly journals Reference Values for Bone Mineral Density and Bone Turnover Markers in the General Elderly Population: A Japanese Cohort Survey Randomly Sampled From A Basic Resident Registry

Author(s):  
Ryosuke Tokida ◽  
Masashi Uehara ◽  
Yukio Nakamura ◽  
Noriko Sakai ◽  
Shota Ikegami ◽  
...  

Abstract The aim of this study was to provide definitive reference values for bone mineral density (BMD) and bone turnover markers in the general elderly population. Registered citizens of 50 to 89 years old were targeted for this survey. After random sampling from the resident registry of Obuse town, we established eight groups based on age (50s, 60s, 70s, and 80s) and gender. A total of 411 people were enrolled. We used a dual-energy x-ray absorptiometry device to measure and evaluate BMD. The bone formation marker bone alkaline phosphatase (BAP) was measured as a bone turnover marker. Bone resorption markers, including pentosidine, urinary total deoxypyridinoline, urinary type I collagen N-telopeptide, tartrate-resistant acid phosphatase 5b (TRACP-5b), 25-hydroxyvitamin D, and whole PTH were also measured as bone turnover markers.Sixty-three people (15.3%) were diagnosed as OP. In women, BMD decreased with age. On the other hand, there was no characteristic change with age in men. As for bone markers, 25(OH)D, whole parathyroid hormone, and BAP showed no characteristics associated with gender and aging. In terms of the association between low BMD and bone markers, there was a significant association between low BMD and TRACP-5b in females.In conclusions, BMD decreased with age in women. However, there was no decline with age in men. All bone metabolism markers showed no significant characteristics associated with age or gender, except for a significant association between low BMD and TRACP-5b in females. TRACP-5b was a potentially useful marker for the detection of low BMD.

2014 ◽  
Author(s):  
Mingo Dominguez Maria Luisa de ◽  
Sonsoles Guadalix Iglesias ◽  
Maria Begona Lopez Alvarez ◽  
Guillermo Martinez Diaz-Guerra ◽  
Federico Hawkins Carranza

2019 ◽  
Vol 17 (4) ◽  
pp. 102-106
Author(s):  
M. Yu. Smetanin ◽  
◽  
S. Yu. Nurgalieva ◽  
N. Yu. Kononova ◽  
L. T. Pimenov ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
A. Sánchez ◽  
L. R. Brun ◽  
H. Salerni ◽  
P. R. Costanzo ◽  
D. González ◽  
...  

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab.Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.


Sign in / Sign up

Export Citation Format

Share Document